Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Anti-RhD; Anti-Rhesus D; Anti-rhesus D immunoglobulin Gs; Anti-rhesus D polyclonal antibodies; Sym-001; Symphoglobulin-D

Latest Information Update: 13 Apr 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Symphogen
  • Class Immunoglobulins; Polyclonal antibodies; Recombinant proteins
  • Mechanism of Action Rh-Hr blood group system inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic thrombocytopenic purpura
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Haemolytic disease of newborn; Idiopathic thrombocytopenic purpura

Most Recent Events

  • 01 May 2013 Rozrolimupab is considered to be outside Symphogen's oncology focus, and its further development is dependent on identification of a global partner
  • 01 May 2013 Suspended - Phase-II for Haemolytic disease of newborn in Germany (IM)
  • 01 May 2013 Suspended - Phase-II for Haemolytic disease of newborn in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top